Tag Archives | abiraterone approval

Zytiga (abiraterone acetate) price will impact the Prostate Cancer market following FDA approval

Sally Church on Pharma Strategy Blog has written about the FDA approval yesterday of Ortho Biotech’s ($JNJ) abiraterone acetate, brand name Zytiga for the treatment of castration resistant prostate cancer in patients who have received prior chemotherapy with docetaxel. The final data showed a 4.6 month increase in overall survival (OS) in these very sick […]

Continue Reading